Regeneron, Alnylam win FDA nod for myasthenia gravis therapy
Regeneron and Alnylam received FDA approval for Livsayis (cemdisiran), an RNA therapy for myasthenia gravis in adults. The drug was jointly developed by the two companies.
How this was made

The 30-second read
Why it matters
A regulatory approval is a discrete catalyst that can change valuation assumptions for both the primary developer and the platform partner, even without revenue guidance in the excerpt.
Market read
Traders may adjust biotech exposure and relative positioning in RNAi names based on the new FDA-approved product catalyst.
What to watch
The article excerpt omits label details, launch timeline, and any financial terms of the REGN-ALNY collaboration, which can materially affect how much incremental value is actually realized.
Background
The FDA approval covers Livsayis (cemdisiran), an RNA therapeutic for adults with myasthenia gravis, developed with Alnylam’s involvement.
Ticker impact
Regeneron received U.S. approval for Livsayis (cemdisiran), an RNA therapeutic for adults with myasthenia gravis, signaling a new commercial product.
Likely positive repricing as the market adds probability-weighted sales from a newly approved myasthenia gravis therapy.
The article states a direct regulatory approval event for REGN’s product, which is typically material for biotech valuation even without financial guidance details.
Alnylam is named as the developer partner for Livsayis (cemdisiran), which the FDA approved for myasthenia gravis treatment.
Likely upward bias as investors price in improved platform validation and potential partner economics.
The text links ALNY to the approved RNA therapeutic, but provides no explicit financial terms, limiting precision on magnitude.
Market effects
Reinforces investor appetite for RNAi therapeutics and can lift sentiment across the small group of RNA platform developers and partners.
Primarily US biotech sentiment, with potential spillover to global biotech peers trading on FDA approval momentum.
Supports the broader global narrative that RNA therapeutics are progressing through late-stage regulatory milestones.
Counterpoint
Approval headlines can fade if uptake, pricing, or competitive positioning are unclear; without launch timing and commercial data, the market may already be partially positioned.
Key entities
- companyRegeneron Pharmaceuticals
Received U.S. approval for Livsayis (cemdisiran) for adults with myasthenia gravis.
- companyAlnylam Pharmaceuticals
Partnered in developing the RNA therapeutic Livsayis (cemdisiran) that received FDA approval.
- productLivsayis (cemdisiran)
RNA therapeutic approved by the FDA for adults with myasthenia gravis.




